Harbin Pharmaceutical Group Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Harbin Pharmaceutical Co., Ltd.") is a large-scale enterprise group that integrates pharmaceutical manufacturing, trade, and scientific research. Listed on the Shanghai Stock Exchange in June 1993 (stock code "600664"), it is the first listed company in the pharmaceutical industry in China and also the first listed company in Heilongjiang Province. The company covers three core business sectors: industrial manufacturing, commerce, and GNC. It has 10 industrial enterprises, including Harbin Pharmaceutical Sanjing, Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Sixth Factory, and Harbin Pharmaceutical Shiyitang. It also has two commercial circulation enterprises, Harbin Pharmaceutical Rentong Tai (a listed company) and Harbin Pharmaceutical Marketing. It also has a strong research and development force in pharmaceutical research institutes, focusing on innovative research and development in high-tech fields such as central nervous system, anti-tumor drugs, and cardiovascular and cerebrovascular drugs. Harbin Pharmaceutical Co., Ltd. has 1816 drug approvals and 74 health food approvals. Its main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric aminophene Huang Namin granules, lacidipine tablets, cefotiam hydrochloride for injection, ibuprofen granules, and Xingai Zhonggai brand high calcium tablets. The company has 5 well-known Chinese trademarks, including "Harbin Pharmaceutical", "Sanjing", "Gaizhonggai", "Hutong", and "Shiyitang", with a brand value of over 20 billion yuan. Integrity and professionalism, openness and inclusiveness, collaboration and responsibility, and innovation and efficiency are the core values of enterprise development. Harbin Pharmaceutical Co., Ltd. is a highly innovative and pioneering enterprise. In the future, the company will coordinate the talent chain, industry chain, and capital chain, comprehensively build an open innovation ecosystem, continuously explore high-quality development paths, and strive to break through transformation in multiple fields such as products, technology, research and development, intelligent manufacturing, business models, and management mechanisms, making Harbin Pharmaceutical a benchmark for Chinese ethnic pharmaceutical enterprises that consumers, customers, employees, and society are proud of. |
| Headquarter | Harbin |
| Establish Date | 12/28/1991 |
| Listed Code | 600664.SH |
| Listed Date | 6/29/1993 |
| Chairman | Zhang Yichen. |
| CEO | Lin Ren. |
| Website | www.hayao.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
